Position in SVTR
Snapshot 2026-11-08- Startup SignalsTop 5%↓3
- Life Sciences#1of 252–
- AI for Science#1of 117–
- Drug Discovery#1of 73–
About
Isomorphic Labs is a drug discovery company spun out of DeepMind and founded in 2022 in London, applying AI to drug discovery and design including protein structure prediction via AlphaFold.
Technology & BusinessWhat · How · Which stage
Research AreasLife SciencesMedicine & PharmaMediumEvidence
AI 驱动的药物设计平台（IsoDDE 引擎）：预测蛋白质结构、设计新药分子，自建治疗管线并与大型药企合作研发；已与诺华、礼来、强生达成合作
Source：Official site · Updated 2026-09-10 · View source
Full tier & rationale — an SVTR Intelligence benefit
Timeline
Public events aggregated from this page; rating changes are member-only.
Capital graph
Funding history
- 2026-05-12Series B$2.1B
Investors · Thrive Capital, Alphabet, GV, MGX, Temasek Holdings, CapitalG, UK Sovereign AI FundSource · isomorphiclabs.com ↗
- 2025-04Series A$600M
Investors · Alphabet, GV, Thrive CapitalSource · isomorphiclabs.com ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Isomorphic Labs
AI-driven drug design platform (IsoDDE engine): uses AlphaFold-based technology to predict protein structures and design new drug molecules; builds it…
Series B · $2.7B · 2026-05
$2.7B
United States
BusinessLatest roundTotal raisedDate- Valo Health
Computational drug discovery/development platform built on AI and human data…
Series B · $450M · 2021-01
$450M - DeepSeq.AI
AI design and optimization of biologics for large pharma, built on protein language models and large-scale wet-lab data
$620K
$620K - Iambic Therapeutics
Uses AI to predict protein-ligand structures and generate molecular designs to discover new drugs
IPO · $462M · 2026-09
$462M
China
BusinessLatest roundTotal raisedDate- NeuShen Therapeutics
Novel drugs for CNS psychiatric and neurological disorders…
Series B · 2026-09
— - 元示科技
AI Virtual Cell (AIVC): a raw biological data engine and general-purpose cell foundation model forming a life sciences base…
Angel · 2026-10
— - BioGeometry
Generative AI protein/antibody design platforms (GeoFlow, GeoBiologics) and closed-loop dry-wet lab drug discovery
Series A · $100M · 2026-10
$100M
Europe
BusinessLatest roundTotal raisedDate- Relation Therapeutics
Multi-omics plus active graph machine learning to discover and validate novel drug targets, partnered with GSK (fibrosis and osteoarthritis)
Undisclosed · $61M · 2025-12
$61M - Allox
AI and high-throughput genetics to map protein allostery, developing small-molecule drugs for hard-to-drug targets
Seed · 2026-10
— - Rivercell
In-house automated wet lab generating large-scale single-cell perturbation data to train "AI virtual cell" models that predict human cell responses to…
Seed · 2026-10
—
Other / unspecified
BusinessLatest roundTotal raisedDate- Galux
AI plus physics-based protein/antibody design platform (GaluxDesign) for drug discovery
Series B · $58M · 2026-02
$58M - Halmos Labs
AI-driven automated R&D systems for biotech and pharma that simulate experimental outcomes before wet-lab work and recommend the experiments that most…
— - 深度细胞
Combines AI with multiscale molecular physics to build a "virtual cell world model" for disease mechanism discovery and drug design
Seed · $14M · 2026-08
$14M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Y Combinator
39 Life Sciences deals in the last 24 months · 21 at a nearby stage · 1 in United Kingdom
Request intro →Alumni Ventures
12 Life Sciences deals in the last 24 months · 5 at a nearby stage · 1 in United Kingdom
Request intro →Accel
12 Life Sciences deals in the last 24 months · 7 at a nearby stage · 2 in United Kingdom
Request intro →Catalio Capital Management
9 Life Sciences deals in the last 24 months · 7 at a nearby stage · 1 in United Kingdom
Request intro →LifeX Ventures
8 Life Sciences deals in the last 24 months · 2 at a nearby stage · 1 in United Kingdom
Request intro →Index Ventures
8 Life Sciences deals in the last 24 months · 3 at a nearby stage · 1 in United Kingdom
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.